Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4 2023
Initiated a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor, in adult healthy volunteers
Cash, cash equivalents and marketable securities of $332.3 million as of June 30, 2023, are expected to fund planned operations into 2025
Ventyx to host conference call and webcast today at 4:30PM ET
Ventyx will host a conference call today at 4:30 p.m. ET to discuss its second quarter 2023 financial results and provide a corporate update. To participate in the conference call, please dial (800) 225-9448 (U.S.) or (203) 518-9708 (international) and reference passcode VTYXQ223. A live audio webcast will be available in the Investors section of the company’s website at www.ventyxbio.com. A recording of the webcast will be available for thirty days following the call.
https://finance.yahoo.com/news/ventyx-biosciences-reports-second-quarter-200100689.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.